Ketamine has been used safely as an anesthetic in medical settings for decades, but its use as a rapid-acting treatment for depression is one of the more significant developments in psychiatry in recent memory not because it is merely another antidepressant, but because it operates through an entirely different biological mechanism than anything that came before it. Understanding what that mechanism actually is matters for patients who are trying to make sense of why treatments they have already tried have not worked. At The Mood Center in Annapolis and Columbia, Maryland, we believe that science-literate patients make better decisions about their care, so here is what the research actually shows.
Why Traditional Antidepressants Work the Way They Do and Why That Matters
To understand what makes ketamine different, it helps to understand the approach that preceded it. The antidepressants most commonly prescribed today SSRIs and SNRIs increase the availability of serotonin and norepinephrine in the brain. They do this by blocking the reabsorption of those neurotransmitters after they are released, keeping them active in the synaptic gap longer. For many people, this is genuinely effective. For others, it is not. For a deeper look at how these two treatment approaches compare clinically, see our overview of ketamine therapy vs. traditional antidepressants.
The limitation of the monoamine model the framework that treats depression primarily as a serotonin or norepinephrine deficiency is that it does not account for the full neurobiological complexity of the condition. Research increasingly points to the glutamate system as a key factor in cases where serotonin-targeted treatment falls short (PMC). Glutamate is the brain’s primary excitatory neurotransmitter. It is involved in synaptic plasticity, learning, memory formation, and the neural circuits that regulate mood. When the glutamate system is dysregulated as it is in many cases of depression adjusting serotonin levels alone may not address the underlying problem.
This is the gap ketamine fills. And it fills it fast. For a broader look at how this shift is reshaping psychiatric care, see how ketamine clinics are revolutionizing depression treatment.
The NMDA Receptor: What Ketamine Actually Blocks
Ketamine’s primary mechanism of action involves blocking a specific class of receptors called NMDA receptors N-methyl-D-aspartate receptors which are distributed throughout the brain and play a central role in synaptic transmission and plasticity (PMC). When glutamate is released and binds to NMDA receptors under normal conditions, it triggers a series of downstream signals that regulate how neurons communicate, strengthen, and adapt. In depression, this process goes wrong in ways that result in weakened synaptic connections and reduced neural circuit function, particularly in the prefrontal cortex and hippocampus regions critical for mood regulation, motivation, and emotional processing.
When ketamine blocks NMDA receptors, it disrupts this dysregulated pattern and triggers a compensatory response. The brain, sensing the interruption, releases a burst of glutamate through alternative pathways. This surge activates a different receptor type AMPA receptors and initiates a cascade of cellular events that are now understood to be core to ketamine’s antidepressant effect. This cascade happens within minutes of the infusion beginning, which is why patients sometimes notice shifts during the treatment itself rather than weeks later.
Neuroplasticity: The Brain’s Repair Response
The most consequential downstream effect of this glutamate cascade is the promotion of neuroplasticity the brain’s capacity to form new synaptic connections, reorganize neural networks, and repair pathways that have been damaged or weakened by chronic stress and depression. Ketamine has been shown to meaningfully promote this process (PMC), which distinguishes it fundamentally from medications that work primarily by maintaining higher levels of existing neurotransmitters.
Think of it this way. Traditional antidepressants are, in a sense, turning up the volume on a conversation the brain is already trying to have. Ketamine does something structurally different it helps rebuild the neural architecture through which that conversation occurs. For patients whose depression has persisted for years or who have been through multiple medication trials without adequate relief, this distinction is clinically significant. The problem may not have been a simple chemical deficit. It may have been a structural one that required a structural solution.
This neuroplastic response also helps explain why ketamine can produce antidepressant effects within hours rather than the weeks that oral antidepressants typically require. Research published in Nature Translational Psychiatry confirms that ketamine produces rapid and significant antidepressant effects in clinical studies effects that emerge on a timeline fundamentally different from anything the monoamine-targeting medications produce (Nature).
BDNF: The Growth Signal
Central to the neuroplasticity story is a protein called brain-derived neurotrophic factor, or BDNF. Think of BDNF as the brain’s primary growth and repair signal it supports the survival of existing neurons, encourages the growth of new ones, and facilitates the formation of synaptic connections. Depression is associated with reduced BDNF levels, particularly in the hippocampus. Ketamine has been shown to increase BDNF meaningfully, and this increase is considered one of the mechanisms through which it promotes the synaptic regeneration underlying its antidepressant effects (PMC).
This is not a minor footnote. The BDNF mechanism helps explain why ketamine does not merely suppress depressive symptoms in the short term but may actually begin to reverse some of the structural brain changes that chronic depression produces. At The Mood Center, our six-infusion IV ketamine protocol over three weeks is designed to allow this neuroplastic process to build across multiple sessions each infusion adding to the structural repair that the previous one initiated.
SPRAVATO® and the Same Mechanism in a Different Form
For patients who may be candidates for an insurance-covered option, SPRAVATO® (esketamine) an FDA-approved nasal spray derived from ketamine works through the same glutamate-NMDA mechanism. SPRAVATO® is specifically FDA-approved for treatment-resistant depression in adults and for major depressive disorder with suicidal thoughts or actions. It is administered at our clinic under medical supervision and used in conjunction with an oral antidepressant. We are in-network with CareFirst, Anthem, Aetna, Cigna, United Healthcare, Tricare, Maryland Medicaid, and Medicare, and SPRAVATO® is covered by most of these plans for approved conditions.
Understanding that IV ketamine and SPRAVATO® share a mechanism helps patients frame their options clearly. They are not entirely different treatments they are different delivery forms of the same underlying pharmacological approach. Which is more appropriate depends on your clinical history, your insurance situation, and what you and your provider decide together.
Addressing Two Common Barriers
The stigma around ketamine is real and worth addressing directly. Because ketamine has a history of misuse as a recreational drug, some patients approach it with understandable wariness wondering whether they are being offered something experimental, dangerous, or outside the mainstream of psychiatric care. The honest answer is that ketamine has been used as a medical anesthetic safely for decades, that its antidepressant application has been studied extensively in peer-reviewed clinical research, and that SPRAVATO® is an FDA-approved medication. At the doses and under the clinical protocols we use, it is not the substance that concerns people when they hear the name. It is a different application of a well-understood compound. Results vary by individual, and our team will discuss candidacy, contraindications, and realistic expectations honestly before any treatment begins. Our ketamine FAQ page is a good starting point if you have questions before reaching out.
The other barrier is scheduling. We hear consistently from patients in the Annapolis and Columbia areas that finding time for a treatment course is genuinely difficult particularly for working adults managing careers, families, and other obligations. Our evening and Saturday appointment availability at both locations exists precisely for this reason. A six-session treatment course over three weeks should not require putting your professional life on hold.
Frequently Asked Questions
How is ketamine different from antidepressants I have already tried? Standard antidepressants primarily target serotonin and norepinephrine, adjusting the availability of those neurotransmitters over weeks of daily dosing. Ketamine works through the glutamate system by blocking NMDA receptors, triggering a rapid neuroplastic response that can produce antidepressant effects within hours. The mechanism is fundamentally different, which is why patients who have not responded to multiple antidepressants sometimes respond to ketamine the biological target is not the same.
Is the rapid effect a sign that it wears off quickly? Not necessarily. The immediate effect of NMDA receptor blockade is indeed short-lived, but the neuroplasticity it initiates the formation of new synaptic connections and the increase in BDNF extends over days and can be consolidated through a full treatment course. Our six-infusion protocol and maintenance booster sessions are designed to sustain the structural brain changes that produce durable relief. Results vary by individual.
Do I need to stop taking my current antidepressants to try ketamine? No. We do not want any disruption in patient-prescribed medications, and ketamine can be used alongside existing antidepressants. SPRAVATO® is specifically designed to be used in conjunction with an oral antidepressant. Discuss your current medication regimen with our team and with your prescribing provider before treatment begins, and we will advise based on your individual circumstances.
What is the difference between IV ketamine and SPRAVATO® at your clinic? IV ketamine is administered intravenously over 45 minutes in a private room at our clinic. It is self-pay and not currently covered by insurance $425 per session, or $395 per session when purchasing a package of 6, which is our standard initial course. SPRAVATO® is an FDA-approved esketamine nasal spray that patients self-administer under supervision and is covered by most major insurance plans for approved conditions, including treatment-resistant depression; co-pays vary by plan and our team verifies benefits and handles prior authorization. Both work through the glutamate-NMDA mechanism. Which is more appropriate for you depends on your diagnosis, treatment history, and insurance coverage something we discuss in the free consultation.
Key Takeaways
Ketamine works through the glutamate system by blocking NMDA receptors, producing a neuroplastic cascade that is fundamentally different from how SSRIs and SNRIs operate.
The downstream effects of NMDA blockade include a surge in BDNF the brain’s primary growth and repair protein which helps explain ketamine’s capacity to produce rapid antidepressant effects and begin reversing the structural brain changes associated with chronic depression.
Research confirms that ketamine produces rapid and significant antidepressant effects on a timeline entirely distinct from oral antidepressants, often within hours of a single infusion.
SPRAVATO® (esketamine) operates through the same mechanism and is FDA-approved for treatment-resistant depression and MDD with suicidal ideation, with coverage available through most major insurers at our clinic.
Results vary by individual, and we approach every treatment decision collaboratively discussing your full history, realistic expectations, and all available options before recommending a course of care.
The neuroscience of ketamine explains something that patients have been experiencing clinically for years: that when nothing else has worked, this is different. If you have been through multiple antidepressant trials without finding adequate relief, we encourage you to schedule a free consultation at our Annapolis or Columbia clinic. Call 443-940-MOOD or book online to have an honest conversation about whether ketamine therapy or SPRAVATO® may be a clinically appropriate option for you.
References
PMC. NMDA receptor / glutamate system. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
PMC. Ketamine and neuroplasticity. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/
PMC. Ketamine increases BDNF. https://pubmed.ncbi.nlm.nih.gov/39684808/
Nature. Ketamine’s effectiveness for depression. https://www.nature.com/articles/s41398-021-01327-5
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy and SPRAVATO® (esketamine) should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. The neuroscientific mechanisms described in this article represent general findings from published research and do not constitute a guarantee of treatment outcomes for any specific patient. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
